Sensorion pivots to new gene therapy for hearing loss: Australian trial plans underway

The new gene therapy, SENS-601, targets a larger patient population, people with mutations in the GJB2 gene, the leading cause of congenital genetic deafness. Image: Hadi Incredible/stock.adobe.com. French hearing-loss biotechnology company Sensorion has selected its next-generation gene therapy, SENS-601, as its lead hearing restoration program, while discontinuing development of its earlier SENS-501 treatment that...

No actionable change — this is an early-stage pipeline announcement with no trial results yet; audiologists should monitor for future trial outcomes but need not change practice.

GJB2 mutations are the single most common cause of inherited deafness, so a targeted gene therapy entering clinical trials could eventually offer a biological treatment option alongside conventional amplification for a well-defined patient population.

1. 01Sensorion has selected SENS-601 as its next gene therapy program, targeting GJB2 mutations.
2. 02GJB2 mutations are the leading genetic cause of congenital (present-from-birth) deafness.
3. 03Australian clinical trials are planned, though no start date or phase was specified in the report.
4. 04This represents a pivot for Sensorion toward genetic hearing loss after earlier pipeline work.
5. 05No efficacy or safety data are available yet — the program is pre-clinical-results stage.